Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07844213
NA

Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"

Sponsor: China National Center for Cardiovascular Diseases

View on ClinicalTrials.gov

Summary

The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2022-08-25

Completion Date

2025-08-31

Last Updated

2026-09-28

Healthy Volunteers

No

Interventions

DRUG

Control group (ambrisentan plus tadalafil or macitentan plus tadalafil)

The control group received dual drug therapy: endothelin receptor antagonists (Ambrisentan 10mg qd, or Macitentan 10mg qd) combined with phosphodiesterase type 5 inhibitors (Tadalafil 20-40mg qd).

DRUG

Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)

The treatment group received early triple therapy: endothelin receptor antagonist (Ambrisentan 10 mg qd or Macitentan 10 mg qd), a phosphodiesterase type 5 inhibitor ( Tadalafil 20-40 mg qd), and treprostinil. The Treprostinil dose was titrated gradually, starting at 1.25 ng/min/kg and escalated to the patient's maximum tolerated dose (target dose range: 15-20 ng/min/kg).

Locations (1)

Fuwai Hospital, National Center for Cardiovascular Diseases

Beijing, China